Sign up to save your podcasts
Or
Share Emerging Evidence in Second-Line and Potential Considerations in First-Line aGC and GEJ cancers
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Emerging Evidence in Second-Line and Potential Considerations in First-Line aGC and GEJ cancers
CME credits: 0.25
Valid until: 21-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-in-second-line-and-potential-considerations-in-first-line-agc-and-gej-cancers/14038/
HER2 is an essential biomarker to be assessed in all patients with gastric/GEJ cancer. Its importance is not only related to its role as a therapeutic target for pathway inhibition, but also to its ability to anchor the application of non-HER2 pathway therapeutic strategies with direct and bystander impact in the tumor microenvironment. Join Drs. Janjigian and Klempner as they delve into historical and exciting emerging data that may well bring new hope to your patients with gastric/GEJ cancers.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 21-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-in-second-line-and-potential-considerations-in-first-line-agc-and-gej-cancers/14038/
HER2 is an essential biomarker to be assessed in all patients with gastric/GEJ cancer. Its importance is not only related to its role as a therapeutic target for pathway inhibition, but also to its ability to anchor the application of non-HER2 pathway therapeutic strategies with direct and bystander impact in the tumor microenvironment. Join Drs. Janjigian and Klempner as they delve into historical and exciting emerging data that may well bring new hope to your patients with gastric/GEJ cancers.
=